Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Toxic Protein Complexes Promote Development of Multiple Neurodegenerative Disorders

By LabMedica International staff writers
Posted on 15 Sep 2008
Neuroscientists have identified a mechanism that explains why patients suffering from severe neurodegenerative diseases such as Alzheimer's disease often develop other syndromes such as Parkinson's disease and vice versa.

The mechanism is linked to the misfolding and pathologic aggregation of neuronal proteins, which has been proposed to play a critical role in the pathogenesis of neurodegenerative disorders. More...
Progressive accumulation of amyloid beta protein (Abeta) oligomers has been identified as one of the central toxic events in Alzheimer's disease, while accumulation of alpha-synuclein (alpha-syn) results in the formation of oligomers and protofibrils in Parkinson's disease.

Investigators from the University of California, San Diego (San Diego, CA, USA) used immunoblots, molecular modeling, and in vitro studies performed with alpha-syn and Abeta in order to understand the molecular mechanisms involved in potential Abeta/alpha-syn interactions. They reported in the September 4, 2008, issue of the journal Public Library of Science (PLoS) ONE that Abeta and alpha-syn co-immunoprecipitated and formed complexes. Molecular modeling and simulations showed that Abeta bound alpha-syn monomers, homodimers, and trimers, forming hybrid ring-like pentamers. Interactions occurred between the N-terminus of Abeta and the N-terminus and C-terminus of alpha-syn. The stable pentamers acted as nanopores that altered neuronal activity and would likely contribute to the mechanisms of neurodegeneration in Alzheimer's and Parkinson's diseases.

"Clinically, we knew that having one neurological disease, such as Alzheimer's, put patients at risk for another neurological disease in combination with it, for example, Parkinson's disease or frontotemporal dementia. But as doctors and scientists, we did not understand why this occurred until now,” explained senior author Dr. Eliezer Masliah, professor of neurosciences and pathology at the University of California, San Diego. "This sort of modeling, to determine the structure of these complexes, was never before possible. With this novel technology, we have come to a new understanding of these combined neurological diseases, and have a model for developing new drugs to treat them.”

Related Links:
University of California, San Diego



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.